Lilly downsizes Va. plant

Two years behind schedule, Eli Lilly says it will cut plans for a new manufacturing facility in Virginia and hire only half of the 700 workers it originally promised when lining up millions of dollars in public support for the project. Analysts say that sagging demand for insulin products helped inspire the cutbacks. Public officials say that the project is still worth the more than $7 million in economic incentives offered by the county and state.

- read this article from The Washington Post for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.